{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T22:50:25Z","timestamp":1778539825937,"version":"3.51.4"},"reference-count":20,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2022,8,9]],"date-time":"2022-08-09T00:00:00Z","timestamp":1660003200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2023,4]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Antistaphylococcal penicillins and cefazolin are the treatments of choice for methicillin-susceptible Staphylococcus aureus (MSSA) infections, requiring multiple doses daily. At Parkland, eligible uninsured patients with MSSA bloodstream infections (BSI) receive self-administered outpatient parenteral antimicrobial therapy (S-OPAT). Ceftriaxone was used in a cohort of S-OPAT patients for ease of once-daily dosing.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>A retrospective study was conducted to evaluate clinical outcomes for patients discharged with ceftriaxone versus cefazolin to treat MSSA BSI.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A retrospective cohort noninferiority study design was used to assess treatment efficacy of ceftriaxone versus cefazolin among Parkland S-OPAT patients treated from April 2012 to March 2020. Demographic, clinical, and treatment-related adverse events data were collected. Clinical outcomes included treatment failure as defined by repeat positive blood culture or retreatment within 6 months, all-cause 30-day readmission rates, and central line\u2013associated bloodstream infection (CLABSI) rates.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Of 368 S-OPAT patients with MSSA BSI, 286 (77.7%) received cefazolin, and 82 (22.3%) received ceftriaxone. Demographics and comorbidities were similar for both groups. There were no treatment failures in the ceftriaxone group compared with 4 (1%) in the cefazolin group ( P = 0.58). No difference in 30-day readmission rate between groups was found. The CLABSI rates were lower in ceftriaxone group (2%) compared with cefazolin (11%; P = 0.02). Limitations include retrospective cohort design.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Ceftriaxone was found to be noninferior to cefazolin in this study. Our findings suggest that ceftriaxone is a safe and effective treatment of MSSA BSI secondary to osteoarticular or skin and soft tissue infections when used in the S-OPAT setting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Poster abstract:<\/jats:title>\n                    <jats:p>OFID on 2018 Nov; 5(Suppl 1): S316: doi: 10.1093\/ofid\/ofy210.894.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10600280221115460","type":"journal-article","created":{"date-parts":[[2022,8,9]],"date-time":"2022-08-09T03:03:44Z","timestamp":1660014224000},"page":"425-431","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":6,"title":["Safety and Efficacy of Ceftriaxone in the Treatment of Methicillin-Susceptible\n                    <i>Staphylococcus aureus<\/i>\n                    Bloodstream Infections: A Noninferiority Retrospective Cohort Study"],"prefix":"10.1177","volume":"57","author":[{"given":"Anisha","family":"Ganguly","sequence":"first","affiliation":[{"name":"Internal Medicine Residency Program, University of Washington Medical Center, Seattle, WA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolina","family":"de la Flor","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3196-6118","authenticated-orcid":false,"given":"Kristin","family":"Alvarez","sequence":"additional","affiliation":[{"name":"Parkland Health, Dallas, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L. Steven","family":"Brown","sequence":"additional","affiliation":[{"name":"Parkland Health, Dallas, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3765-4644","authenticated-orcid":false,"given":"Norman S.","family":"Mang","sequence":"additional","affiliation":[{"name":"Parkland Health, Dallas, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jillian","family":"Smartt","sequence":"additional","affiliation":[{"name":"Parkland Health, Dallas, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen","family":"King","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9539-2358","authenticated-orcid":false,"given":"Trish M.","family":"Perl","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hector","family":"Filizola","sequence":"additional","affiliation":[{"name":"University of Texas Southwestern Medical Center, Dallas, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7861-6425","authenticated-orcid":false,"given":"Kavita P.","family":"Bhavan","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA"},{"name":"Parkland Health, Dallas, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2022,8,9]]},"reference":[{"key":"bibr1-10600280221115460","doi-asserted-by":"publisher","DOI":"10.1086\/512627."},{"key":"bibr2-10600280221115460","doi-asserted-by":"publisher","DOI":"10.1086\/527389."},{"key":"bibr3-10600280221115460","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00134-14."},{"key":"bibr4-10600280221115460","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199808203390806."},{"key":"bibr5-10600280221115460","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.39.8.1764"},{"key":"bibr6-10600280221115460","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00019-10."},{"key":"bibr7-10600280221115460","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics9020039."},{"key":"bibr8-10600280221115460","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2010.03425.x."},{"key":"bibr9-10600280221115460","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofy089."},{"key":"bibr10-10600280221115460","doi-asserted-by":"publisher","DOI":"10.1007\/s11908-017-0599-0."},{"key":"bibr11-10600280221115460","doi-asserted-by":"publisher","DOI":"10.1007\/s11096-014-9999-5."},{"key":"bibr12-10600280221115460","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir857."},{"key":"bibr13-10600280221115460","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-013-0477-0."},{"key":"bibr14-10600280221115460","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001922."},{"key":"bibr15-10600280221115460","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.15391."},{"key":"bibr16-10600280221115460","unstructured":"Bhavan KP. Self-administered IV innovation drives simplicity, affordability, accessibility. NEJM Catal Innov Care Deliv. 2020. Accessed April 19, 2021. https:\/\/catalyst.nejm.org\/doi\/abs\/10.1056\/CAT.20.0421."},{"key":"bibr17-10600280221115460","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaa341."},{"key":"bibr18-10600280221115460","doi-asserted-by":"publisher","DOI":"10.1080\/1120009X.2019.1680116."},{"key":"bibr19-10600280221115460","doi-asserted-by":"publisher","DOI":"10.2165\/0003088-200948020-00002."},{"key":"bibr20-10600280221115460","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1808312."}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280221115460","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10600280221115460","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280221115460","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:17:00Z","timestamp":1777375020000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10600280221115460"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,9]]},"references-count":20,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["10.1177\/10600280221115460"],"URL":"https:\/\/doi.org\/10.1177\/10600280221115460","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,9]]}}}